- Home
- RUM vs DVAX Comparison
RUM vs DVAX Comparison
Compare RUM & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUM
- DVAX
- Stock Information
- Founded
- RUM 2013
- DVAX 1996
- Country
- RUM United States
- DVAX United States
- Employees
- RUM N/A
- DVAX N/A
- Industry
- RUM Computer Software: Prepackaged Software
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- RUM Technology
- DVAX Health Care
- Exchange
- RUM Nasdaq
- DVAX Nasdaq
- Market Cap
- RUM 2.0B
- DVAX 1.7B
- IPO Year
- RUM N/A
- DVAX 2004
- Fundamental
- Price
- RUM $8.09
- DVAX $12.90
- Analyst Decision
- RUM Hold
- DVAX Buy
- Analyst Count
- RUM 2
- DVAX 2
- Target Price
- RUM $8.00
- DVAX $22.00
- AVG Volume (30 Days)
- RUM 4.3M
- DVAX 1.3M
- Earning Date
- RUM 11-12-2024
- DVAX 11-07-2024
- Dividend Yield
- RUM N/A
- DVAX N/A
- EPS Growth
- RUM N/A
- DVAX N/A
- EPS
- RUM N/A
- DVAX 0.15
- Revenue
- RUM $85,651,775.00
- DVAX $260,810,000.00
- Revenue This Year
- RUM $19.36
- DVAX $21.64
- Revenue Next Year
- RUM $18.49
- DVAX $19.81
- P/E Ratio
- RUM N/A
- DVAX $85.33
- Revenue Growth
- RUM 6.36
- DVAX N/A
- 52 Week Low
- RUM $3.33
- DVAX $9.74
- 52 Week High
- RUM $9.20
- DVAX $15.01
- Technical
- Relative Strength Index (RSI)
- RUM 60.68
- DVAX 57.32
- Support Level
- RUM $7.81
- DVAX $12.66
- Resistance Level
- RUM $8.92
- DVAX $13.17
- Average True Range (ATR)
- RUM 0.63
- DVAX 0.29
- MACD
- RUM 0.07
- DVAX -0.04
- Stochastic Oscillator
- RUM 62.44
- DVAX 48.08
About RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.